Clonidine versus Captopril for Severe Postpartum Hypertension: A Randomized Controlled Trial

Area of Science:

• Obstetrics
• Cardiology
• Pharmacology

Background:

• Postpartum (puerperium) changes in women with hypertension require further clarification.
• Optimal antihypertensive selection for managing severe postpartum hypertension is not well-defined.
• Existing data do not clearly guide the choice of postpartum antihypertensives.

Purpose of the Study:

• To compare the effectiveness and safety of clonidine versus captopril in treating severe postpartum hypertension.
• To evaluate the frequency of severe blood pressure episodes and need for rescue medication.
• To assess adverse reactions in postpartum women receiving either clonidine or captopril.

Main Methods:

• A randomized, triple-blind, drug-controlled clinical trial was conducted.
• Ninety postpartum women with severe hypertension (SBP ≥180 mmHg and/or DBP ≥110 mmHg) were randomized into two groups (45 each).
• One group received captopril, while the other received clonidine, with outcomes including severe blood pressure episodes and adverse events.

Main Results:

• The clonidine group had fewer severe blood pressure episodes (2.1 vs. 3.5) and a greater SBP reduction (14.0% vs. 10.8%), though not statistically significant (p=0.08).
• Fewer women in the clonidine group required sodium nitroprusside (2.3% vs. 13.3%, p=0.06).
• Mean SBP on the third postpartum day was significantly lower in the clonidine group (151.9 mmHg vs. 158.1 mmHg, p=0.02), and adverse reactions were less common (18.6% vs. 28.8%).

Conclusions:

• Both clonidine and captopril are safe and effective treatments for severe postpartum hypertension.
• Clonidine may offer a favorable profile with potentially fewer adverse events and better blood pressure control in certain postpartum periods.